3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
9
Unknown
3
Recruiting
2
Not yet recruiting
2
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
3
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Carcinoma, Renal Cell
2
Bites and Stings
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Oligoprogressive
1
Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Gemcitabine
34
pembrolizumab
26
Paclitaxel
21
Cyclophosphamide
21
Docetaxel
20
Carboplatin
20
Irinotecan
19
Capecitabine
19
Fluorouracil
17
Bevacizumab
15
Dexamethasone
14
fludarabine
13
Oxaliplatin
13
Leucovorin
13
Blood Specimen Collection
13
Everolimus
12
Cetuximab
12
Ipilimumab
11
Erlotinib Hydrochloride
11
Rituximab
10
Pemetrexed
10
Cisplatin
10
venetoclax
9
Temozolomide
9
Sunitinib
9
Nivolumab
9
Trastuzumab
8
Interleukin-2
8
aldesleukin
7
Epoetin Alfa
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms
×
Immune Checkpoint Inhibitors
×
Clear all
NCT05716295
2024-05-08
ORCHID-1
Medikine, Inc.
Phase 1/2
Terminated
26 enrolled